Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01506609
Title The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie

breast cancer


Temozolomide + Veliparib

Carboplatin + Etoposide + Veliparib

Carboplatin + Paclitaxel

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | CAN | BEL

No variant requirements are available.